Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Antoinette Tan"'
Autor:
Alice P. Chen, Antoinette Tan
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
Externí odkaz:
https://doaj.org/article/ef17dbee104a486eabd607c907c706fa
Autor:
Marcin Kowanetz, Manish Sharma, Jeeyun Lee, Leisha Emens, Keun-Wook Lee, Yoon-Koo Kang, Paula Pohlmann, Glenn Hanna, Ecaterina Ileana Dumbrava, Daniel Catenacci, Dejan Juric, Bob Li, Kathleen Moore, Mark Pegram, Antoinette Tan, Shelley Ackerman, Heidi LeBlanc, David Dornan, Michael Alonso, Edith Perez
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/167f6142b7f044179c143cbfa94d4cf3
Publikováno v:
AIAA SCITECH 2023 Forum.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d86a09d9db6052c8167c9b52dd9df47c
https://doi.org/10.2514/6.2023-2577
https://doi.org/10.2514/6.2023-2577
Autor:
Antoinette Tan, Whitney Q. Lohmeyer
Publikováno v:
2022 IEEE International Symposium on Phased Array Systems & Technology (PAST).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::001bdce0a9b6f3b10837eb166220285c
https://doi.org/10.1109/past49659.2022.9975051
https://doi.org/10.1109/past49659.2022.9975051
Autor:
Kush C. Gaur, Justin Tiu-Lim, Julie McGrath, Phil Walker, Michael Korn, Joanne Xiu, Arielle Heeke, Virginia Kaklamani, Antoinette Tan, Janice Lu, Darcy Spicer, Evanthia Roussos-Torres, Priya Jayachandran, Audrey Saghian, Amir Goldkorn, Irene Kang
Publikováno v:
Cancer Research. 82:5793-5793
BACKGROUND FGFR signaling is central for cancer cell proliferation, migration, angiogenesis, and survival. The frequency and type of FGF/FGFR aberrations are not well-characterized across invasive breast cancer subtypes and metastatic sites of diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7bd096d114fc1669a8cac335a0d4c67a
https://doi.org/10.1158/1538-7445.am2022-5793
https://doi.org/10.1158/1538-7445.am2022-5793
Autor:
Sung-Bae Kim, Rebecca Dent, Seock-Ah Im, Marc Espié, Sibel Blau, Antoinette R Tan, Steven J Isakoff, Mafalda Oliveira, Cristina Saura, Matthew J Wongchenko, Amy V Kapp, Wai Y Chan, Stina M Singel, Daniel J Maslyar, José Baselga, Keun Seok Lee, Hwei-Chung Wang, Antoinette Tan, Joo Hyuk Sohn, Michelino De Laurentiis, Laura Garcia Estevez, Chiun-Sheng Huang, Gilles Romieu, Michel Velez, Rafael Villanueva, Pier Franco Conte, Shaker Dakhil, Marc Debled, Antonio Gonzalez Martin, Sara Hurvitz, Jee Hyun Kim, Christelle Levy, Pedro Sanchez Rovira, Jae Hong Seo, Vicente Valero, Gregory Vidal, Andrea Wong, Mary Ann K Allison, Robert Figlin, David Chan, Shin-Cheh Chen, Yen-Hsun Chen, Melody Cobleigh, Filippo De Braud, Luc Dirix, Vincent Hansen, Anne Hardy Bessard, Nicholas Iannotti, Steven Isakoff, William Lawler, Alvaro Montaño, Mohamad Salkini, Leonard Seigel
Publikováno v:
The Lancet. Oncology, vol 18, iss 10
Summary Background The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-negative breast cancer. The LOTUS trial investigated the addition of ipatasertib to paclita
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23bb66843d8ecfd467caeec1baf17b8a
https://escholarship.org/uc/item/7z70q2hf
https://escholarship.org/uc/item/7z70q2hf
